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This study evaluates the efficacy of capecitabine using data from a large, well-characterised population of patients with metastatic
colorectal cancer (mCRC) treated in two identically designed phase III studies. A total of 1207 patients with previously untreated
mCRC were randomised to either oral capecitabine (1250mgm
 2 twice daily, days 1 14 every 21 days; n¼603) or intravenous
(i.v.) bolus 5-fluorouracil/leucovorin (5-FU/LV; Mayo Clinic regimen; n¼604). Capecitabine demonstrated a statistically significant
superior response rate compared with 5-FU/LV (26 vs 17%; Po0.0002). Subgroup analysis demonstrated that capecitabine
consistently resulted in superior response rates (Po0.05), even in patient subgroups with poor prognostic indicators. The median
time to response and duration of response were similar and time to progression (TTP) was equivalent in the two arms (hazard ratio
(HR) 0.997, 95% confidence interval (CI) 0.885–1.123, P¼0.95; median 4.6 vs 4.7 months with capecitabine and 5-FU/LV,
respectively). Multivariate Cox regression analysis identified younger age, liver metastases, multiple metastases and poor Karnofsky
Performance Status as independent prognostic indicators for poor TTP. Overall survival was equivalent in the two arms (HR 0.95,
95% CI 0.84–1.06, P¼0.48; median 12.9 vs 12.8 months, respectively). Capecitabine results in superior response rate, equivalent
TTP and overall survival, an improved safety profile and improved convenience compared with i.v. 5-FU/LV as first-line treatment for
MCRC. For patients in whom fluoropyrimidine monotherapy is indicated, capecitabine should be strongly considered. Following
encouraging results from phase I and II trials, randomised trials are evaluating capecitabine in combination with irinotecan, oxaliplatin
and radiotherapy. Capecitabine is a suitable replacement for i.v. 5-FU as the backbone of colorectal cancer therapy.
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The fluoropyrimidine 5-fluorouracil (5-FU) has remained the most
extensively used chemotherapeutic agent in the treatment of
advanced colorectal cancer for more than 40 years. During this
time, many 5-FU-based regimens have been developed, including
48-h infusion or continuous infusions of 5-FU that are considered
by many to be the safest and most effective.
Capecitabine (Xeloda
s: F Hoffmann-La Roche, Basel, Switzer-
land) is an oral fluoropyrimidine carbamate rationally designed to
generate 5-FU preferentially in tumour tissue through exploitation
of higher intratumoral concentrations of thymidine phosphorylase
(Miwa et al, 1998; Schu ¨ller et al, 2000). Human pharmacokinetic
studies have shown that after oral administration, capecitabine is
rapidly and almost completely absorbed through the gastrointest-
inal wall, thus avoiding direct intestinal exposure to 5-FU (Reigner
et al, 2001). Capecitabine is then metabolised to 5-FU via a three-
step enzymatic cascade. The final stage of this conversion is
mediated by thymidine phosphorylase, an enzyme present at
significantly increased concentrations in a wide range of tumour
types, including colorectal, breast and gastric cancers, compared
with normal tissue (Miwa et al, 1998). The tumour-preferential
activation of capecitabine reduces systemic exposure to 5-FU and
potentially improves efficacy and safety (Schu ¨ller et al, 2000).
As an oral agent, capecitabine enables dosing that approximates
to continuous infusion 5-FU with improved convenience. Con-
ventional infused 5-FU regimens require central venous access via
a Port-a-Cath
s, Hickman catheter or Groshong and the use of
Received 10 November 2003; revised 16 December 2003; accepted 17
December 2003; published online 24 February 2004
*Correspondence: Prof E Van Cutsem;
E-mail: eric.vancutsem@uz.kuleuven.ac.be
British Journal of Cancer (2004) 90, 1190–1197
& 2004 Cancer Research UK All rights reserved 0007– 0920/04 $25.00
www.bjcancer.com
C
l
i
n
i
c
a
lportable pumps, causing considerable inconvenience to patients.
In addition, the rate of complications such as thrombosis and
infection is reported to be as high as 20–60% with chronic venous
access devices (Hartkamp et al, 2000; Schwarz et al, 2000). These
factors, together with the known patient preference for oral
chemotherapy (Liu et al, 1997; Borner et al, 2002), generated the
need for an oral agent such as capecitabine that could achieve
continuous exposure to 5-FU in a similar manner to infused
regimens.
A randomised, phase II trial in patients with advanced colorectal
cancer demonstrated that capecitabine is well tolerated and has
substantial antitumour activity (Van Cutsem et al, 2000).
Subsequently, two multicentre, open-label, phase III studies were
conducted to compare capecitabine with intravenous (i.v.) 5-FU/
leucovorin (5-FU/LV; Mayo Clinic regimen, the regulatory
standard at the time), as first-line treatment for metastatic
colorectal cancer (mCRC)(Hoff et al, 2001; Van Cutsem et al,
2001a). One study was conducted in Europe, Australia, Israel and
Asia and the other was conducted in the USA, Canada, Brazil and
Mexico. Both studies used identical protocols and an integrated
analysis of all data was prospectively planned. The integrated
analysis has provided an opportunity to retrospectively assess the
use of capecitabine in a large, well-characterised population of
patients with mCRC. Safety evaluation demonstrated that capeci-
tabine has an improved safety profile compared with 5-FU/LV,
with a significantly lower incidence of diarrhoea, stomatitis,
nausea and alopecia. The lower incidence of Grade 3–4
neutropaenia with capecitabine led to significantly less neutro-
paenic fever/sepsis and consequently fewer hospitalisations
(Cassidy et al, 2002). The improved safety profile of capecitabine
also results in better utilisation of medical resources, leading to a
pharmacoeconomic advantage for capecitabine over i.v. 5-FU. This
was demonstrated in an analysis of medical resource use in the
European randomised trial (Twelves et al, 2001). The safety data
from the two trials have been reviewed extensively by Cassidy et al
(2002). This paper provides a detailed review of the efficacy
analyses of the pooled data.
PATIENTS AND METHODS
Trial design
The two studies used identical protocols and conduct, with the
primary objective of establishing that oral capecitabine achieves a
response rate at least equivalent to i.v. 5-FU/LV in patients with
previously untreated mCRC (a-level of 2.5% and an equivalence
margin of 10%). Secondary objectives were to compare additional
efficacy parameters, including time to disease progression (TTP),
overall survival, duration of response and time to first response, as
well as safety and quality of life profiles and medical resource
utilisation during treatment.
All patients recruited to the trials had received no prior
cytotoxic chemotherapy for metastatic disease. Adjuvant or neo-
adjuvant therapy completed at least 6 months prior to enrolment
was permitted.
Treatment
Patients were randomised to receive either oral capecitabine
(1250mgm
 2 twice daily for 14 days followed by a 7-day rest
period) or 5-FU/LV administered according to the Mayo Clinic
regimen (LV 20mgm
 2 followed by 5-FU 425mgm
 2, adminis-
tered as an i.v. bolus on days 1–5 every 28 days) (Hoff et al, 2001;
Van Cutsem et al, 2001a). The standard capecitabine dose
reduction scheme, described in detail elsewhere (Cassidy et al,
2002), was used for management of adverse events. Patients were
treated for up to 48 weeks until disease progression or
unacceptable toxicity. Treatment continuation beyond 48 weeks
was permitted in patients without progressive disease at the
discretion of the investigator (poststudy treatment phase).
Evaluation of efficacy
Tumour evaluations were made at baseline and then at 6-weekly
intervals during study treatment, based on standard World Health
Organization (1979) criteria. In addition to the investigator
assessment, an Independent Review Committee (IRC), consisting
of a panel of radiologists who were blinded to study treatment,
clinical condition of the patient and investigator’s assessment,
evaluated tumour responses solely on the basis of imaging.
RESULTS
Patient population
In total, 1207 patients were randomised to treatment with
capecitabine (603 patients) or 5-FU/LV (604 patients). All patients
were included in the efficacy analysis. The demographic and
baseline characteristics of patients in the two groups were well
balanced (Table 1). As expected, in both treatment groups, the
majority of patients had colon rather than rectal cancer. The
proportions of patients who had previously received adjuvant
chemotherapy were similar in the two groups and there was no
significant difference between the groups with respect to extent or
sites of metastatic disease. In general, there were no differences in
the distribution of prognostic factors at baseline; although
significant differences in serum alkaline phosphatase concentra-
tions favouring the 5-FU/LV group were observed in one study
(Hoff et al, 2001), no significant differences were apparent in the
integrated data (Table 2).
The median duration of treatment was 4.5 months in the
capecitabine group and 4.6 months in the 5-FU/LV group. Safety
data, including data on treatment interruption and dose modifica-
tion, are described in detail elsewhere (Cassidy et al, 2002).
Table 1 Demographics and baseline characteristics
Capecitabine 5-FU/LV
(n¼603) (n¼604)
Male/female (%) 60/40 61/39
Age (years): median (range) 64 (23–86) 63 (24–87)
KPS (%): mean (range) 89 (70–100) 89 (70–100)
Colon/rectal cancer (%) 70/30 71/29
Tumour differentiation (%)
Well differentiated 11 11
Moderately differentiated 62 63
Poorly differentiated 19 17
Undetermined/unknown 8 10
Number of metastatic sites (%)
12 5 2 2
22 4 2 1
X35 2 5 7
Metastatic sites (%)
Liver 77 77
Lung 33 33
Lymph nodes 33 35
Peritoneum 14 14
Prior adjuvant chemotherapy (%) 24 26
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Results from the integrated analysis demonstrate a significantly
superior overall response rate with capecitabine compared with 5-
FU/LV (26 vs 17%, Po0.0002; Table 3). Notably, the superior
efficacy of capecitabine was confirmed by the IRC-assessed
response rate (22 vs 13%, Po0.0001). Furthermore, analysis of
the data according to subpopulations defined by baseline
characteristics consistently demonstrated superior response rates
for capecitabine compared with 5-FU/LV (Po0.05; Figure 1). In
both treatment arms, response rates decreased with increasing
numbers of metastatic sites, as would be expected. Of note, in
patients who had previously received adjuvant chemotherapy, the
response rate with capecitabine was 21% (31 out of 147 patients)
compared with only 9% (14 out of 155) in patients treated with 5-
FU/LV.
Response to treatment occurred at least as rapidly in patients
treated with capecitabine compared with patients who received 5-
FU/LV (median time to response: 1.7 vs 2.4 months, respectively).
The median duration of response was also similar in the two
treatment groups (8.1 and 9.4 months in the capecitabine and 5-
FU/LV groups, respectively).
Time to disease progression
TTP was equivalent in the two treatment groups (hazard ratio
(HR) 0.997, 95% confidence interval (CI) 0.885 1.123, log-rank
P¼0.95). The median TTP was 4.6 months (95% CI 4.3 5.3) with
capecitabine and 4.7 months (95% CI 4.3 5.4) with 5-FU/LV
(Figure 2). Subgroup analysis according to baseline characteristics,
including cancer type (rectal vs colon cancer), history of adjuvant
chemotherapy and gender, demonstrated no significant differences
between the two treatment groups for TTP.
Regression analyses were undertaken to assess the impact of
prognostic factors on TTP for the entire population. Univariate
Cox regression analyses including treatment as a covariable were
performed, and identified a number of factors associated with
reduced TTP. These included poor Karnofsky performance status
(KPS; 70 vs 100%), liver metastases, multiple metastatic sites and
younger age, with prognostic significance at a level of 15%
(Table 4). Previous adjuvant treatment and gender did not appear
to impact on disease progression. A multivariate Cox regression
analysis using backward elimination of factors, with the first step
including all factors identified in the univariate analyses, was then
performed to assess the impact of independent prognostic factors
on the treatment effect at a significance level of 5%. This analysis
confirmed an increased risk of progression with lower age, liver
metastases, poor KPS (70 or 80% at baseline) and multiple
metastatic sites (Table 5). Of note, the analyses confirmed that risk
of disease progression was independent of treatment, as indicated
by the HR of 1.02 (95% CI 0.90–1.15; P¼0.79).
Overall survival
Overall survival data, updated in June 2002 after 1147 events,
confirm the integrated analysis results reported by Twelves (2002).
In patients receiving capecitabine, overall survival was equivalent
to that in patients treated with 5-FU/LV (HR 0.95, 95% CI
0.84 1.06, P¼0.48). The median survival was 12.9 months (95%
CI 11.8 14.0) in the capecitabine group and 12.8 months (95% CI
11.7 14.0) in the 5-FU/LV group after 583 and 564 events,
respectively (Figure 3). Univariate analyses identified nine
prognostic factors for survival with a significance level of 15%.
Multivariate Cox regression analysis confirmed that lower KPS (70
or 80 vs 100%), multiple metastatic sites and the presence of liver
Table 2 Distribution of prognostic factors in the two treatment groups
(mean values7s.d.)
Capecitabine
(n¼603)
5-FU/LV
(n¼604)
Wilcoxon test
ZP -value
Alkaline phosphatase
a (U/l) 142.9 (121.2) 135.5 (116.4)  1.7 0.091
ASAT (IU) 21.5 (15.5) 20.7 (15.7)  1.5 0.13
Haemoglobin (g/dl) 12.9 (1.9) 12.9 (1.9) 0.2 0.87
aNormalised serum alkaline phosphatase. ASAT¼aspartate aminotransferase.
Table 3 Investigator-assessed tumour response rates
Capecitabine 5-FU/LV
(n¼603) (n¼604) P-value
PR+CR (%) 25.7 16.7 o0.0002
95% CI 22.4–29.6 13.8–19.9
Stable disease (%) 48.3 52.2
95% CI 43.7 51.8 48.1 56.2
PR¼partial response, CR¼complete response.
Capecitabine (n = 603)
5-FU/LV (n = 604)
* P < 0.05  
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Figure 1 Response rates by subpopulation.
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lmetastases were independent prognostic indicators for poor
survival (Table 6). Patients with well-differentiated tumours had
a slightly reduced risk of death compared with patients having less
well-differentiated tumours. The data also suggest that previous
surgery may have a prognostic effect, but the number of patients
who did not have prior surgery was extremely small, as
approximately 90% of patients had received prior surgery.
Similarly, multivariate Cox regression analysis suggested that risk
of death was markedly reduced in patients defined as race ‘other’
compared with the rest of the population (HR¼0.64). However,
this subgroup, comprising multiple ethnic groups (including
Orientals and Hispanics), included only 35 patients in the
capecitabine arm and 34 patients in the 5-FU/LV arm, and thus
the results are difficult to interpret. Of note, the analyses
confirmed that survival was independent of treatment. In addition
to the predefined prognostic factors, baseline serum alkaline
phosphatase, ASAT, serum albumin and haemoglobin were all
confirmed as prognostic factors for survival in a secondary
analysis (Table 7).
Both irinotecan monotherapy (Cunningham et al, 1998; Rougier
et al, 1998) and oxaliplatin in combination with 5-FU/LV (Andre ´
et al, 1999; Maindrault-Goebel et al, 1999) have proven efficacy in
patients with mCRC that has progressed during/following previous
5-FU-based therapy. Therefore, the impact of second-line che-
motherapy on survival in the capecitabine phase III trials was also
evaluated. The results of this analysis demonstrated that a similar
number of patients in the capecitabine and 5-FU/LV groups
received second-line chemotherapy (55 and 56% of patients,
respectively). However, the choice of treatment was different for
patients in the two treatment groups: among patients receiving
second-line therapy, those in the capecitabine group received
second-line 5-FU-based treatment more frequently than patients in
the 5-FU/LV arm (54 vs 35%, P¼0.00001, Table 8) (Twelves, 2001).
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Figure 2 Time to disease progression.
Table 5 Results of multivariate Cox regression analysis: TTP
Both treatment
groups Capecitabine group
Factor HR P-value HR P-value
Predominant metastatic site: liver 1.38 0.0001 1.46 0.0001
Metastatic sites (41 vs 1) 1.42 0.0001 1.61 0.0001
KPS
70 vs 100% 1.55 0.0001 1.52 0.0018
80 vs 100% NA NA 1.32 0.018
Age 0.99 0.013 0.99 0.0001
NA¼not available.
Table 4 Results of univariate Cox regression analysis: TTP
Both treatment
groups Capecitabine group
Factor HR P-value HR P-value
Liver metastases (yes vs no) 1.37 0.0001 1.39 0.0016
Metastatic sites (41 vs 1) 1.39 0.0001 1.55 0.0001
KPS
70 vs 100% 1.67 0.0009 1.61 0.0010
80 vs 100% 1.14 0.29 1.36 0.017
90 vs 100% 1.02 0.83 1.16 0.17
Previous adjuvant therapy (yes vs
no)
1.00 0.96 0.92 0.39
Large (410 patients) vs small
(p10 patients) recruitment/
treatment center
1.01 0.94 0.88 0.15
Age 0.99 0.045 0.99 0.0008
Gender 0.92 0.36 1.03 0.70
Capecitabine (n = 603)
5-FU/LV (n = 604)
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Figure 3 Overall survival: updated June 2002.
Table 6 Results of multivariate Cox regression analysis: survival
Factor HR P-value
Treatment 0.99 (0.87–1.13) 0.90
Country Mexico 2.71 0.0002
Predominant metastatic site: liver 1.38 0.0001
KPS
70 vs 100% 2.34 0.0001
80 vs 100% 1.66 0.0001
Differentiation (well vs other) 0.77 0.016
Previous surgery 0.77 0.014
Number of metastatic sites 1.06 0.013
Metastatic sites (1 vs more) 1.29 0.013
Race ‘other’
a 0.64 0.033
aOriental (n¼8), Hispanic (n¼23) and all races other than Caucasian and Black.
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a smaller proportion of those patients who received second-line
treatment in the capecitabine arm than in the 5-FU/LV arm (29 vs
41%, respectively, Po0.001) (Twelves, 2001). The timing and
duration of second-line treatment was similar in the two groups.
DISCUSSION
The common mode of action of 5-FU and oral fluoropyrimidines
predicts similar efficacy for these two approaches. For this reason,
trials comparing oral fluoropyrimidines and conventional i.v. 5-
FU/LV regimens in the treatment of colorectal cancer generally
require demonstration of equivalent efficacy between the two
agents. However, the results of this integrated analysis demon-
strated that as first-line therapy for mCRC, capecitabine offers a
superior response rate and equivalent time to progression and
survival compared with i.v. bolus 5-FU/LV. The efficacy of
capecitabine therefore compares favourably with that of other
oral fluoropyrimidines evaluated in patients with mCRC. Recently,
two large, independent, phase III trials in a total of more than 1400
patients demonstrated that the dihydropyrimidine dehydrogenase
inhibitor eniluracil in combination with oral 5-FU is less effective
than 5-FU/LV (Mayo Clinic regimen) as first-line treatment for
mCRC (Van Cutsem et al, 2001b; Schilsky et al, 2002). Overall
survival was significantly inferior with eniluracil/oral 5-FU vs 5-
FU/LV in one trial and TTP was significantly inferior with
eniluracil/5-FU in the other. Similarly, a large phase III trial in 816
patients failed to demonstrate equivalent efficacy for UFT/LV and
5-FU/LV (Mayo Clinic regimen). In this study, the risk of disease
progression was increased by 22% in patients receiving the
investigational therapy, UFT/LV (P¼0.011, HR 0.823, 95% CI
0.708–0.958) (Douillard et al, 2002; Schmoll, 2003). Whereas the
current analysis demonstrates superior response rates for capeci-
tabine vs 5-FU/LV, the overall response rates for UFT/LV and 5-
FU/LV did not differ significantly between treatment arms, with a
trend to a lower response rate for UFT/LV. Capecitabine is the only
oral fluoropyrimidine that has demonstrated efficacy at least
equivalent to that of 5-FU/LV (Mayo Clinic regimen) as first-line
therapy for colorectal cancer, leading to its regulatory approval
worldwide in this indication.
The superior response rate observed with capecitabine com-
pared with 5-FU/LV was seen consistently in all subpopulation
analyses. Patients with poor prognostic indicators, such as poor
KPS and liver metastases, were more likely to respond if treated
with capecitabine than with 5-FU/LV. The superior response rate
was particularly pronounced in the subpopulation of patients who
had previously received adjuvant 5-FU. However, even among
patients not previously exposed to fluoropyrimidines of any kind,
the response rate was superior for those receiving capecitabine.
A multivariate analysis of survival to evaluate the impact of
prognostic factors confirmed the primary analysis of survival,
demonstrating that survival was independent of treatment
administered. Evaluation of the impact of second-line treatment
on survival outcomes demonstrated that poststudy treatment
favoured the 5-FU/LV group, and therefore strengthens the claim
that capecitabine results in efficacy at least equivalent to that
achieved with 5-FU/LV.
An integrated analysis of safety data from the phase III trials has
also demonstrated that capecitabine has an improved safety profile
compared with 5-FU/LV, with a significantly (Po0.001) lower
incidence of diarrhoea (47.7 vs 58.2%), stomatitis (24.3 vs 61.6%),
nausea (37.9 vs 47.6%) and alopecia (6.0 vs 20.6%) (Cassidy et al,
2002). The only adverse event occurring significantly more
frequently with capecitabine was hand-foot syndrome (53.5 vs
6.2% with 5-FU/LV, Po0.001). This cutaneous side effect is readily
managed by treatment interruption and dose reduction and led to
hospitalisation of only two patients (both for o24h). The lower
incidence of Grade 3–4 neutropaenia (2.3 vs 22.8%) with
capecitabine compared with 5-FU/LV led to significantly
(Po0.001) less neutropaenic fever/sepsis (0.2 vs 3.4%) and
consequently fewer hospitalisations (Cassidy et al, 2002). Grade
4 adverse events were more common with 5-FU/LV than with
capecitabine (5.1 vs 3.0%, respectively; P¼0.078), mostly compris-
ing neutropaenia-related complications and diarrhoea. The
incidence of grade 3 or 4 treatment-related adverse events during
the first treatment cycle was significantly higher in patients
receiving 5-FU/LV than in those receiving capecitabine (22.6 vs
9.1%, respectively; Po0.001).
The results of this integrated analysis therefore support the use
of capecitabine as first-line monotherapy for advanced colorectal
cancer. As an effective oral agent, capecitabine meets patients’
needs for a convenient, oral treatment suitable for outpatient
therapy. In addition, analysis of medical resource use demon-
strated that significantly fewer patients required hospitalisation
for treatment-related adverse events (11.6 vs 18.0%, Po0.005),
and fewer physician visits were required for treatment
Table 7 Prognostic value of baseline factors: survival
Wald test
HR P-value
Alkaline phosphatase(U/l)
a 1.003 0.0001
Treatment interaction 1.000 0.91
ASAT (IU) 1.017 0.0001
Treatment interaction 1.003 0.33
Albumin (gdl) 0.975 0.0001
Treatment interaction 0.958 0.0001
Haemoglobin (gdl) 0.870 0.0001
Treatment interaction 0.971 0.39
aNormalised serum alkaline phosphatase.
Table 8 Second-line chemotherapy: incidence, timing and duration
Capecitabine 5-FU/LV
Second-line
treatment
% of patients receiving second-line
therapy (n¼334)
Treatment
start
a
Duration
(days)
% of patients receiving
second-line therapy
(n¼340)
Treatment
start
a
Duration
(days)
Irinotecan 29 192 66 41 185 60
Oxaliplatin 3 289 71 6 169 71
5-FU 54 168 59 35 194 64
aMedian days from randomisation to start of second-line chemotherapy.
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ladministration with capecitabine than with 5-FU/LV (4 vs 15 in a
12-week period).
Combination chemotherapy is becoming increasingly common
in patients who can tolerate intensive therapy. Two phase III
studies have demonstrated that the addition of irinotecan to bolus
or infused 5-FU/LV provides a modest but statistically significant
survival benefit in the first-line treatment of patients with
colorectal cancer (Douillard et al, 2000; Saltz et al, 2000). However,
there are certain patient subgroups for whom first-line combina-
tion therapy may not be the most appropriate treatment strategy.
For example, in patients with poor performance status and
elevated serum LDH, irinotecan/5-FU/LV combination therapy
did not appear to confer a survival benefit. In the subgroup of
patients who had previously received adjuvant therapy, overall
survival was reduced compared with the overall patient population
(FDA Medical Officer Summary, 1999; Knight et al, 2000). In a
multivariate analysis of almost 4000 patients, Ko ¨hne et al (2002)
identified four clinical parameters (performance status, WBC
count, alkaline phosphatase concentration and number of involved
tumour sites) enabling grouping of patients into low-, medium- or
high-risk categories. Assessment of risk for each patient potentially
facilitates decisions on whether more or less intensive treatments
are most appropriate for each individual. Recently published
National Comprehensive Cancer Network (NCCN) guidelines
(National Comprehensive Cancer Network Clinical Practice Guide-
lines in Oncology, 2003) recommend that in patients who cannot
tolerate intensive combination therapy, fluoropyrimidine mono-
therapy is the most appropriate treatment strategy. In this context,
capecitabine provides a highly active first-line treatment option.
The ECOG and EORTC are currently planning a study in poor-
prognosis patients comparing capecitabine monotherapy vs
capecitabine/irinotecan combination therapy vs capecitabine/
oxaliplatin combination therapy. Results of this trial should
provide insight into the optimisation of treatment strategies for
patients with a poor prognosis.
Another important consideration when comparing sequential vs
combination therapy in the first-line setting is the tolerability of
the two approaches. The analyses of the NCCTG 9741 and CALGB
89803 randomised phase III trials have raised concerns about the
safety of irinotecan in combination with bolus 5-FU/LV, with an
unexpectedly high number of early deaths leading to modification
or closure of treatment arms combining bolus 5-FU/LV regimens
with irinotecan or oxaliplatin (Morton et al, 2001; Rothenberg et al,
2001; Ratain, 2002).
Irinotecan/fluoropyrimidine therapy might be better tolerated
when 5-FU/LV is administered as a protracted infusion, and recent
data from the NCCTG trial also suggest that combination therapy
with infused 5-FU/LV may provide efficacy advantages over those
incorporating a bolus regimen (Goldberg et al, 2004). Capecita-
bine, which approximates to continuous infusion 5-FU and has an
improved safety profile compared with bolus 5-FU, potentially
provides a better-tolerated combination partner for irinotecan.
Recently results from two trials evaluating first-line capecitabine
plus irinotecan, (n¼37 and 52) showed response rates of 43 and
46% and median time to progression of 9.3 and 7.1 months,
respectively (Borner et al, 2003; Patt et al, 2003). Phase III
evaluation of capecitabine/irinotecan combination therapy is
ongoing. Capecitabine is also in the early stages of evaluation in
combination with oral irinotecan, thus offering potential for all-
oral combination therapy for patients with colorectal cancer.
Similarly, clinical studies have demonstrated that oxaliplatin in
combination with infused 5-FU/LV is a highly effective first-line
treatment for patients with advanced colorectal cancer, resulting in
superior response rates and TTP compared with 5-FU/LV alone
(de Gramont et al, 2000; Giacchetti et al, 2000). In preclinical
models the combination is more effective if 5-FU is administered
as a continuous infusion. This observation suggests that replacing
cumbersome i.v. 5-FU infusions with oral capecitabine may
represent a more effective, more convenient oxaliplatin combina-
tion therapy than current i.v. 5-FU-based regimens. Mature results
of a phase II, multicentre trial of capecitabine plus oxaliplatin in 96
patients has demonstrated an overall response rate of 55%, with
consistently high (450%) response rates across all patient
subgroups studied (Van Cutsem et al, 2003). In this trial the
median progression-free survival was 7.7 months and median
overall survival was 19.5 months. The regimen had a favourable
safety profile, with a low incidence of grade 3 or 4 treatment-
related adverse events.
An extensive phase III programme is evaluating both capecita-
bine plus irinotecan and capecitabine plus oxaliplatin with or
without biological agents (bevacizumab) in first-line and in the
adjuvant setting.
In addition to combination with irinotecan and oxaliplatin for
the treatment of advanced colorectal cancer, capecitabine has been
evaluated as a combination partner for radiotherapy in the
management of rectal cancer. Preclinical studies demonstrated
that capecitabine and radiotherapy have enhanced antitumour
activity, which is most likely attributable to the further upregula-
tion of thymidine phosphorylase (the enzyme responsible for the
final conversion of capecitabine to 5-FU) in tumour cells following
radiotherapy (Sawada et al, 1999). More recently, a phase II study
demonstrated that capecitabine/radiotherapy combination treat-
ment is feasible with promising activity (Dunst et al, 2003). Phase
II evaluation, particularly in the neo-adjuvant setting, is ongoing
and a phase III trial (NSABP R-04) will compare chemoradiation
with capecitabine vs protracted infusion 5-FU. The addition of
oxaliplatin or irinotecan to capecitabine could further improve
chemoradiation efficacy outcomes in the future, and phase I trials
are ongoing.
Capecitabine is also an attractive agent for use in the adjuvant
setting. A phase III trial to evaluate capecitabine treatment for
Dukes’ C colon cancer completed patient accrual in 2001 and the
safety and efficacy results are eagerly awaited.
The results of this integrated efficacy analysis have confirmed
the results of the two individual trials, showing that capecitabine is
a highly effective agent for the first-line treatment of advanced
colorectal cancer. As first-line therapy, capecitabine results in
superior response rate, is more convenient and has an improved
safety profile compared with 5-FU/LV. Phase I and II studies
evaluating capecitabine in combination regimens indicate that
capecitabine is a very promising and suitable candidate to replace
5-FU as the backbone of colorectal cancer chemotherapy. Phase III
trials should elucidate whether capecitabine may become the
backbone of colorectal cancer combination therapy, not only with
irinotecan, oxaliplatin and radiotherapy but also with novel agents
such as EGFR inhibitors and anti-angiogenic agents.
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